Viewing Study NCT02263495


Ignite Creation Date: 2025-12-24 @ 1:59 PM
Ignite Modification Date: 2026-02-25 @ 8:58 PM
Study NCT ID: NCT02263495
Status: COMPLETED
Last Update Posted: 2020-07-14
First Post: 2014-10-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
Sponsor: Asan Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module